Not to be overshadowed by Apple Watch, AliveCor Announces New 6-Lead ECG Reader – TechCrunch

Apples The announcement last week of a watch with an ECG reader approved by the FDA for tracking heart health seemed to be the cause of the loss of the first company of readers. ECG, AliveCor. But, to prove that he still has a hearty pulse, AliveCor tells TechCrunch that he will be releasing a 6-lead electrocardiogram (ECG) "never seen before," pending FDA approval.

In a care clinic, a patient usually has 12 leads or stickers placed on the chest to collect data from his heart. However, other ECG readers usually have one or two leads. The Apple Watch places a single lead system on the wrist. In theory, the 6-lead ECG reader is more accurate because there are more sensors that collect more information, which could be essential for saving lives.

AliveCor and the current function of the Apple Watch is to detect AFib – or to detect an irregular heartbeat. AliveCor announced earlier this month that it had received FDA approval to use its ECG readers to detect a rare but dangerous condition called hyperkalemia.

According to Vic Gundotra's CEO, the AliveCor device could also detect about 100 different diseases with 6-lead ECG readers. who has shaken a bunch of long illnesses that I can not even begin to pronounce, but he hopes his reader will soon be able to detect.

However, elevated ST is one of the main factors associated with the onset of a heart attack and could lead to a person going to the hospital before it starts to show any other symptoms. physical.

Of course, Apple – which already holds 17% of the notebook market – could easily decide to add a 6-lead ECG reader to the watch and beat the AliveCor market again. But Gundotra shrugs off this suggestion.

"They could, but we have very good patents in the space," he told TechCrunch, adding that "Apple has done an excellent service, actually. business but you talk to me, calling about it [because of their announcement]. "

No official name has yet been announced for the 6 – lead product, but AliveCor will work with the FDA on the regulatory route and hopes to offer it to over – the – counter consumers by 2019.